RED1,2,3: NICE TA373 for treating juvenile idiopathic arthritis (JIA). (Decision date - January 2016)
RED:1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
RED1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016)
RED1,2,3: NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. (Decision date - August 2017)
RED1,2,3: NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)
NHS England is the responsible commissioner for JIA and plaque psoriasis in children and young adults.